par Piccart, Martine;van 't Veer, Laura J;Poncet, Coralie;Lopes Cardozo, Josephine JMN;Delaloge, Suzette;Pierga, Jean-Yves;Vuylsteke, Peter;Brain, Etienne;Vrijaldenhoven, Suzan;Neijenhuis, Peter A;Causeret, Sylvian;Smilde, Tineke J;Viale, Giuseppe;Glas, Annuska M;Delorenzi, Mauro;Sotiriou, Christos 
;Rubio, Isabel Teresa;Kümmel, Sherko;Zoppoli, Gabriele;Thompson, Alastair M;Matos, Erika;Zaman, Khalil;Hilbers, Florentine FS;Fumagalli, Debora ;Ravdin, Peter;Knox, Susan;Tryfonidis, Konstantinos;Peric, Aleksandra;Meulemans, Bart;Bogaerts, Jan;Cardoso, Fatima ;Rutgers, Emiel J T
Référence Lancet oncology
Publication Publié, 2021-03-01
;Rubio, Isabel Teresa;Kümmel, Sherko;Zoppoli, Gabriele;Thompson, Alastair M;Matos, Erika;Zaman, Khalil;Hilbers, Florentine FS;Fumagalli, Debora ;Ravdin, Peter;Knox, Susan;Tryfonidis, Konstantinos;Peric, Aleksandra;Meulemans, Bart;Bogaerts, Jan;Cardoso, Fatima ;Rutgers, Emiel J TRéférence Lancet oncology
Publication Publié, 2021-03-01
Article révisé par les pairs
| Résumé : | The MINDACT trial showed excellent 5-year distant metastasis-free survival of 94·7% (95% CI 92·5-96·2) in patients with breast cancer of high clinical and low genomic risk who did not receive chemotherapy. We present long-term follow-up results together with an exploratory analysis by age. |
